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Abstract
Background: Artemisinins are the newest class of drug approved for malaria treatment. Due to their unique
mechanism of action, rapid effect on Plasmodium, and high efficacy in vivo, artemisinins have become essential
components of malaria treatment. Administration of artemisinin derivatives in combination with other anti-
plasmodials has become the first-line treatment for uncomplicated falciparum malaria. However, their efficiency in
cases of cerebral malaria (CM) remains to be determined.
Methods: The efficacy of several artemisinin derivatives for treatment of experimental CM was evaluated in ICR or
C57BL/6 mice infected by Plasmodium berghei ANKA. Both mouse strains serve as murine models for CM.
Results: Artemisone was the most efficient drug tested, and could prevent death even when administered at
relatively late stages of cerebral pathogenesis. No parasite resistance to artemisone was detected in recrudescence.
Co-administration of artemisone together with chloroquine was more effective than monotherapy with either drug,
and led to complete cure. Artemiside was even more effective than artemisone, but this substance has yet to be
submitted to preclinical toxicological evaluation.
Conclusions: Altogether, the results support the use of artemisone for combined therapy of CM.
Background
The most critical problem currently limiting malaria
treatment is the emergence and spread of parasite resis-
tance to the majority of anti-malarial drugs in use [1].
Improper or incomplete monotherapy of malaria has
caused the development of resistance to the commonly
used chloroquine [2,3] and mefloquine [4], and even to
quinine, which has been a mainstay in the anti-malarial
pharmacopeia for approximately two centuries [5]. Arte-
misinin derivatives comprise the most recently devel-
oped class of anti-malarial drugs currently approved for
human use. These derivatives (Figure 1) include artesu-
nate and artemether, their metabolite dihydroartemisinin
(DHA), and artemisone [6,7]. All artemisinins comprise
a peroxide bridge, essential for activity, embedded
within the 1,2,4-trioxane unit in a fused tetracyclic ses-
quiterpene scaffold.
Artemisinin-type drugs have been proposed to act via
several mechanisms. A widely held view is that ferrous
iron, either ‘free’ or in haemoglobin (Hb), or its break-
down product, haem, is required for activation of the
peroxide [8-11]. Fenton chemistry involving reductive
cleavage of the peroxide by Fe(II) is considered to lead
to C-centered radicals that are the presumed cytotoxic
agents [12]. For haem, it is assumed that the C-radicals
alkylate the haem nucleus to provide adducts that dis-
charge the potent activities of the parent artemisinin
[13,14]. However, artemisinins susceptible to decompo-
sition by haem-Fe(II) display enhanced activities against
parasites cultured under carbon monoxide (CO), an
agent that passivates haem-Fe(II) by formation of stable
haem-Fe(II)-CO complexes; this thereby discounts
haeme as an activator of artemisinins [15,16]. Artemisi-
nins are known mediators of oxidative stress [17] that
enhance oxidative stress in malaria parasites [18,19].
Oxidative damage has been observed to occur in various
parasite membranes [6], the mitochondria [20] and
DNA [21]. Another view, based on the observation that
in vitro anti-malarial activity is sensitive to steric effects,
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binding to a specific protein target site. Artemisinins
have been shown to interfere with the activity of the
Plasmodium falciparum sarcoplasmic/endoplasmic cal-
cium ATPase (SERCA), PfATP6 [22]. SERCA is respon-
sible for the maintenance of calcium ion concentrations,
which is important for the generation of calcium-
mediated signalling as well as for the correct folding
and post-translational processing of proteins. Artemisi-
nins also inhibit endocytosis by the parasite. Although
no direct link has been reported, changes in cytosolic
Ca
+2 levels as a result of SERCA inhibition may have a
significant regulatory effect on endocytosis [23].
The question of plasmodial resistance to artemisinins
has been a matter of debate [6]. However, there is grow-
ing evidence that uncontrolled (non-regulated) use of
these drugs is followed by reduced susceptibility and
resistance [24-26]. An increase in parasite cytochrome
P450 and MDR1 activities may also be the cause of
reduced drug efficacy [27]. Artemisinin-based combina-
tion therapy (ACT) is recommended for more efficient
treatment and for prevention of the induction of drug
resistance [28-32]. A recent review [31] describes
improved results when ACT is used, compared to non-
artemisinin-based combinations. Most of the studies
described were performed using artesunate and were
directed against uncomplicated falciparum malaria.
The search for new anti-malarial therapeutics has
been directed towards identification of new drug targets
in the parasite. As many aspects of the disease and its
complications are caused by the host anti-malarial
immune response, this approach is incomplete. Cerebral
malaria (CM), one of the most serious complications of
P. falciparum infection, affects mainly children and non-
immune adults [33]. In areas of high transmission young
children are more affected by severe malaria, including
CM, as immunity is achieved only after a prolonged per-
iod of exposure, while in low transmission areas CM is
expressed in older children. The pathogenesis of CM
remains unclear. One explanation is adherence and
sequestration of parasitized erythrocytes, peripheral
blood mononuclear cells (PBMC) and platelets to vascu-
lar endothelial cells lining the small blood vessels of the
brain [34]. However, there is no direct proof in humans
for a causative relationship between sequestrations of
PBMC and the pathogenesis of CM. Studies using a
murine model of experimental cerebral malaria (ECM)
with Plasmodium berghei ANKA indicate that ECM is a
T cell-mediated disease. In particular, CD8
+ cytotoxic T
cells are involved in the destruction of the blood-brain
barrier (BBB) by perforin-dependent processes [35-38].
Overall, parasite-triggered cerebral inflammation is con-
sidered to be a possible cause of death from CM
[39,40]. The harmful, dysregulated immune response
leading to CM or ECM is mainly of the Th1 type, with
overproduction of some cytokines, such as IFNg (initially
produced by Th1 cells, and at a later stage also by CD8
+
cytotoxic T cells), combined with underproduction of
others (e.g. IL-10) [41]. Both sequestration and inflam-
mation are needed for induction of cerebral pathogen-
esis [40]. A preventive measure that will eliminate or
reduce even a single factor associated with the cascade
of events leading to (E)CM may completely avert it
[6,42]. In addition to their anti-plasmodial activity, arte-
misinins have been shown to reduce CD4
+ and CD8
+
T cell inflammatory responses [43-46]. The severity of
malarial infection is correlated with both brain endothe-
lial cell activation and blood brain barrier disruption
[47,48]. Vascular endothelial growth factor (VEGF) acti-
vation of vascular and endothelial cells causes disruption
of BBB function as well as angiogenesis in blood vessels
where parasite sequestration has occurred. This results
in haemorrhages and fatal brain oedema, and is thought
to be the source of the neurological impairments seen
in those that survive the infection [49,50]. Artemisinins
have been shown to down-regulate VEGF functions
[51,52]; VEGF down-regulation may alleviate the symp-
toms of CM and reduce the neurological damage in
those who survive the disease [6].
It is apparent that artemisinins, including artemisone,
will be useful for the treatment of CM. Artemisone is
non-neurotoxic, possesses anti-malarial activities greater
than those of artesunate, remains active in the presence
of Hb-Fe(II), does not alkylate haem-Fe(II) under biolo-
gically plausible conditions, and is unaffected by free Fe
(II). In CM, where abnormal quantities of Hb-Fe(II),
haem-Fe(II), or free Fe(II) are present [53], artemisone
will be less prone to competitive degradation.
Thus, it is clear that the suitability of artemisinin-type
drugs for CM prophylaxis and/or therapy merits close
Figure 1 Structures of artemisinin and its derivatives.
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eral artemisinin derivatives on the progression of murine
malaria, with an emphasis on artemisone therapy for
ECM. The possible induction of artemisone resistance and
the efficiency of artemisone monotherapy vs. combined
artemisone-chloroquine treatment is also examined.
Methods
Mice
ICR Harlan-Sprague-Dawley (ICR) or C57Bl/6 Ola-Hsd
male mice (C57Bl/6, from Harlan, Israel; C57Bl/6Aus
from the Animal Resource Centre, Australia:) aged 7-8
weeks were used in all experiments, 6 to 10 mice per
group (as described). The mice were housed under stan-
dard light and temperature conditions and provided
with unlimited access to water and food. All experi-
ments were carried out in accordance with institutional
guidelines for animal care, by protocols approved by the
Animal Ethical Care Committee of The Hebrew Univer-
sity of Jerusalem or the University of Sydney. Parasitae-
mia was monitored every other day, from the time of
inoculation until death or sacrifice, by thin blood smears
prepared from tail blood. These were stained with a 25%
Giemsa solution, examined under a light microscope,
and parasitaemia determined as the number of infected
red blood cells per 10,000 erythrocytes. Clinical signs of
cerebral malaria were evaluated and used for scoring
disease severity (Table 1).
Parasites
Plasmodium berghei ANKA (PbA MRA-311, CDC
Atlanta) was maintained in vivo by serial transfer of
parasitized erythrocytes (PE) from infected to naïve
mice. Experimental mice were infected by intraperito-
neal (i.p.) injection of 5 × 10
4 PE from peripheral blood
of infected donor mice, an inoculum which caused fatal
ECM in at least 50% of infected ICR HSD mice, and
90% of infected C57Bl/6 Ola-Hsd mice. A significant
increase in the inoculum level reduced the incidence of
ECM [54].
In experiments performed at the University of Sydney,
P. berghei ANKA (designated PbAus in the text; cour-
tesy of Prof. G. Grau, University of Sydney, Australia),
was injected to C57Bl/6Aus mice at an inoculum of 10
6
PE. Inoculation of C57Bl/6 mice with PbAus is a well
described model, in which the rate of fatal ECM is at
least 90% [55].
The link between death and ECM in mouse models
has previously been demonstrated [41,56]. Observed
clinical symptoms, including an accelerated drop in core
body temperature and death at low parasitaemias, indi-
cate ECM [48,57,58]. Scoring of disease severity was
performed in order to track the development of ECM,
according to the severity levels described in Table 1.
Infected mice were evaluated for parasitaemia levels, the
appearance of neurological symptoms and changes in
weight and temperature. Clinical signs of neuropathol-
ogy that appear 1-2 days before death from ECM
include marked coat staring, hunching, wobbly gait and
reduced locomotion, convulsions, and coma. Mice that
died at a parasitaemia of 15% or below with accompany-
ing neurological symptoms and drastic reductions in
body weight and temperature were considered to have
died of ECM. ECM death generally occurred on days 8-
10 post-inoculation. Brain pathology observed in mice
dying of ECM includes haemorrhages, mononuculear
cell accumulation in small vessels and the development
of brain oedema. Untreated mice which did not die
from ECM went on to die with severe anaemia and
hyperparasitaemia, as has been reported in all other
cases where mice are resistant to P. berghei ANKA-
induced ECM [59].
Drugs
DHA and artesunate were purchased from the Kunming
Pharmaceutical Corporation via the Hong Kong Univer-
sity of Science and Technology, and used as received.
Artemisone and artemiside were synthesized from DHA
and purified by flash column chromatography, followed
by recrystallization according to the procedure pre-
viously reported [7]. Dimethyl sulfoxide (DMSO) and
chloroquine diphosphate were purchased from Sigma-
Aldrich, Ltd (Israel). All artemisinin derivatives were
prepared in DMSO according to the required dosage
and administered in a volume of 20-50 μl by intraperito-
neal injection. Chloroquine diphosphate was dissolved in
Table 1 Scoring chart for definition and severity of ECM
disease as per clinical signs
Appearance Normal 0
Coat ruffled 1
Coat staring; panting 2
Behaviour (undisturbed) Normal 0
Hunched; wobbly gait 1
Partial paralysis; immobile*
† 2
Convulsions; coma* 3
Food intake Normal 0
Up to 10% loss in body weight 1
10%-15%* loss in body weight 2
More than 15% loss in body weight* 3
Body temperature Normal (36-37°C) 0
34-35°C 1
32-33°C* 2
Below 32°C* 3
Mice with a cumulative score of 5 or above are sacrificed, and death deemed
to be on the following day.
*Endpoint for mouse sacrifice.
†Also in response to stimulation.
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neal injection.
Histology
Mice were deeply anaesthetized and sacrificed by term-
inal intracardial perfusion with 10 ml ice-cold PBS.
Organs were removed and fixed overnight in 10% (v/v)
neutral buffered formalin (Fronine, Australia). Paraffin-
embedded tissues were cut into 5-7 μm slices, deparaffi-
nated, and stained with haematoxylin and eosin before
coverslipping.
Statistics
When comparing parasitaemia values, p values were cal-
culated using Students t-test; for analysis of survival
curves, the Kaplan-Meier test was employed. In both
cases, values below 0.05 were considered significant.
Results
The general approach was to establish the lowest dose
required to save the mice from ECM, using the artemisi-
nin derivatives. Per the results, the most effective drug
was chosen and used to determine the latest day post-
inoculation (as close as possible to the time of overt
ECM expression) at which treatment was still efficient.
Following results depicting recrudescence, experiments
were performed to determine whether recrudescent
parasites displayed any resistance to the drugs used for
treatment. Finally, combination therapy was adminis-
tered to prevent recrudescence and achieve complete
cure.
Mice were treated with the artemisinin derivatives dis-
solved in DMSO or administered the same volume of
DMSO as a control, on different days post-inoculation.
Injection of DMSO itself may partially reduce ECM and
shift the pattern of disease to anemic malaria (see
below). Table 2 depicts the results of an experiment in
which PbA-infected female ICR mice were treated by i.
p. injection of artemisinin derivatives, once a day on
days 2-5 post-inoculation. No significant differences in
the pattern of disease development were seen as a result
of treatment, except in the case of artemiside; adminis-
tration of this drug resulted in complete cure. These
results also suggest that treatment with artemisinins
would necessitate more than one injection per day.
Despite the superior effect of artemiside, the experi-
ments were continued using artemisone, as it has been
already approved for human use [60].
In the next experiment (Figure 2), artemisone was
administered i.p. as a split daily dose on days 3-6 post-
inoculation, to either ICR or C57BL/6 mice infected
with PbA. 90% of control ICR mice died of ECM by day
8; all mice treated with 2 × 2.5 mg/kg/d artemisone
relapsed after an initial drop in parasitemia and died of
ECM, while the higher dose (2 × 5 mg/kg/d artemisone)
was curative in all treated mice (Figure 2A). In C57Bl/6
mice, 70% of DMSO-treated control mice died of ECM.
Administration of 2 × 2.5 mg/kg/d artemisone led to
rapid parasite clearance and complete cure in 50% of
treated mice; recrudescence was observed on day 13
post-inoculation in the remaining mice, which died of
ECM (Figure 2B). Treatment with 2 × 5 mg/kg/day led
to complete cure in both ICR and C57Bl/6 mice. The
differences in survival between all three groups (control
vs. treated, and 2 × 2.5 vs. 2 × 5 mg/kg/d C57Bl/6 mice)
were significant (p < 0.01). Artemisone treatment signifi-
cantly reduced parasitemias (p < 0.001) and increased
survival times, delaying mouse death by up to two
weeks (Figure 3). In ICR mice, the increased survival
time of mice treated with 2 × 5 mg/kg/d artemisone,
compared to control mice, was statistically significant
(p < 0.001), as was the difference in survival time when
treated groups were compared (p < 0.001).
Table 3 presents a summary of experiments performed
to examine the effect of treatment timing on the course
of the disease. C57Bl/6Aus mice were infected with
PbAus and administered artemisone according to differ-
ent schedules. Control mice were divided into two
groups: one group was not treated, while the other was
injected with DMSO in parallel to the drug treatment
schedule. 5/6 non-injected control mice died of ECM on
days 6-9 post-inoculation; DMSO treatment for six suc-
cessive days (2 × 25 μl / d a yo nd a y s3 - 7a n d1×2 5μl/
day on day 8 post-inoculation) reduced the occurrence
of ECM to 3/6 mice (Table 3, groups 1 and 2). Mice
that did not succumb to ECM died of severe anemic
malaria, three weeks later and at high parasitaemias
Table 2 The effect of artemisinin derivatives on the
development of experimental cerebral malaria in PbA-
infected ICR mice
Compound Dose % ECM Delay to ECM
(relative to
control)
DMSO 50 μl 50-90%* -
DHA 5 mg/kg/d 90% -
10 mg/kg/d 70% -
20 mg/kg/d 60% 2 days
Artesunate 2 × 5 mg/kg/
d
65% 9 days**
Artemisone 5 mg/kg/d 100% 2 days
Artemiside 3 mg/kg/d Total cure, no
ECM**
,†
-
Mice (n = 10 mice/group) were treated for two to five days post-inoculation.
Death from ECM was apparent in control mice starting on day 7 post-
inoculation. Mice which did not die of ECM died of severe anemic malaria.
* In 3 experiments.
** Significant
† No recrudescence
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treatment was determined according to parasitaemia
levels: injections began on day 3 or 4 post-inoculation,
when the parasitaemia reached 1%. Treatment with 2 ×
5 mg/kg/day artemisone on days 3-7 or 4-7, followed
by a single injection (5 mg/kg/day) on day 8 post-
inoculation, reduced parasitaemias to below detection
level and led to complete cure in the majority of the
mice. In each group, one mouse recrudesced after 10 or
11 days, developed high parasitaemia and died of severe
anaemic malaria. If treatment was further delayed
to days 5-8 post-inoculation, there was a typical latent
period followed by complete cure (2/5 mice) or
recrudescence and death from severe anaemic malaria
( 3 / 5m i c e )( T a b l e3 ,g r o u p5 ) .N oE C Md e a t h sd u et o
recrudescence were observed. Furthermore, injection of
infected mice with 2 × 20 mg/kg/d artemisone at a very
late stage of the disease, on days 6-8 post-inoculation
(when parasitaemia was ~5%), completely eliminated the
parasites and prevented ECM in all treated mice. The
choice of dose was based on experiments in which 2 × 5
mg/kg was curative (see below): 2 × 20 mg/kg was used
as a measure for the margin of safety and for proof
of concept - that a non-toxic dose can prevent neuro-
pathology. 6/7 control untreated mice died of ECM on
day 7; the remaining mouse died of ECM on day 8.
Figure 2 Development of parasitemia in ICR (A) or C57Bl/6 (B) mice infected with PbA and treated with 2 × 2.5 or 2 × 5 mg/kg/d
artemisone on days 3-6 post-inoculation. D notes mouse death; multiple deaths on a given day are noted in parentheses. Each line
represents a single mouse; arrows denote treatment. ECM death in both control groups occurred on days 8-10 post-inoculation. Administration
of 2 × 2.5 mg/kg/d artemisone was not curative in ICR mice, but led to complete cure in 50% of C57Bl/6 mice; treatment with 2 × 5 mg/kg/day
led to complete cure in both mouse strains.
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Page 5 of 15Figure 3 Survival of ICR (A) or C57Bl/6 (B) mice infected with PbA and administered 2 × 2.5 or 2 × 5 mg/kg/d artemisone on days 3-6
post-inoculation. Significant differences in survival were seen between control and treated groups, in both ICR and C57Bl/6 mice (p < 0.01):
artemisone treatment delayed mouse death by up to two weeks. Arrows denote treatment.
Table 3 Disease pattern in PbAus-infected C57BL/6Aus mice treated with 2 × 5 mg/kg/d rtemisone
Group Compound Treatment*
(days post-inoculation)
Disease pattern
Latency, days Cerebral malaria Anemic malaria Cured**
1 - - 0 5/6 1/6 -
2 DMSO (25 μl) 3-8 0 3/6 3/6 -
3 Artemisone 3-8 10 (n = 1)
† 0/6
† 1/6 5/6
†
4 Artemisone 4-8 11 (n = 1)
† 0/6
† 1/6 5/6
†
5 Artemisone 5-8 10 (n = 4)
† 0/5
† 3/5
‡ 2/5
†,‡
*2 × 5 mg/kg/d every day except day 8 (1 injection, 5 mg/kg/d).
** No recrudescence
†Significant vs. control
‡Significant vs. other artemisone-treated groups
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mice (Figure 4A) demonstrated healthy parenchyma and
intact blood vessels. Neuropathological changes, namely
haemorrhages and leukocyte-packed vessels, were appar-
ent in mice one week post-PbAus inoculation (Figure
4B). In contrast, artemisone-treated mice (Figure 4C)
displayed only minor haemorrhaging; vessels were intact
and clear of leukocytes.
In the case of human Plasmodium infection, early
detection of blood parasites (before symptoms are evi-
dent) is unlikely. Therefore the effect of delayed treat-
ment was examined using artesunate, shown to be more
effective than quinine or quinidine (both recommended
as standard therapy for severe anaemic malaria in the
United States) [61] and artemisone, the most recent
artemisinin derivative approved for clinical trials [60].
The drugs were administered i.p. in 20 μlD M S Oa sa
split daily dose on days 7-9 post-inoculation, to C57Bl/6
mice infected with PbAus. All control mice died of
ECM by day 12 post-inoculation. Following a secondary
rise in parasitaemia after treatment, the mice were again
injected with artesunate or artemisone, on days 20-22
post-inoculation. Figure 5 demonstrates the results of
artemisone vs. artesunate therapy. Administration of 2 ×
Figure 4 Brain histopathology of non-infected C57Bl/6Aus mice (A, B), PbAus-infected C57Bl/6Aus mice on day 6 post-inoculation (C,
D), or infected artemisone-treated C57Bl/6Aus mice on day 8 (E) or 13 (F) post-inoculation. All PbAus-infected control mice died of ECM
on days 7-12 post-inoculation. PbAus-infected mice treated with 2 × 20 mg/kg/d artemisone on days 6-8 post-inoculation were sacrificed on
days 8-13 post-inoculation and brains taken for histology. Histological analysis of brain sections from non-infected mice demonstrated healthy
parenchyma and intact blood vessels. Haemorrhages and leukocyte-packed vessels were apparent in mice one week post-PbAus inoculation
while artemisone-treated mice displayed only minor haemorrhaging; vessels were intact and clear of leukocytes. Arrows indicate hemorrhages
and/or blood vessels.
Waknine-Grinberg et al. Malaria Journal 2010, 9:227
http://www.malariajournal.com/content/9/1/227
Page 7 of 152.5 mg/kg/d artesunate slightly delayed but in general
did not prevent ECM death (p = 0.4); 2 × 5 mg/kg/d
artesunate prevented ECM in most mice (p < 0.0001)
and delayed death from anemic malaria by approxi-
mately one week (p < 0.0001). In contrast, both doses of
artemisone prevented ECM in all treated mice, delayed
recrudescence and prevented death (in 5/8 and 8/8 mice
for 2 × 2.5 mg/kg/d and 2 × 5 mg/kg/d; p < 0.0001 for
treated vs. control mice and for 2 × 2.5 vs. 2 × 5 mg/
kg/d artemisone, respectively; Figure 5A, Table 4). 2 ×
2.5 mg/kg/d artemisone was more effective in delaying
mouse death than the higher do s eo fa r t e s u n a t et e s t e d
(p < 0.01). Changes in mouse temperature (Figure 5B)
and weight (Figure 5C) were in accordance with disease
Figure 5 Parasitemias (A), weights (B), and body temperatures (C) of PbAus-infected C57Bl/6 mice treated with 2 × 2.5 mg/kg/d or 2
× 5 mg/kg/d artesunate or artemisone. Injections (arrows) were given on days 7-9 post-inoculation; control mice were administered 2 × 20 μl
DMSO per day. *p < 0.001, control vs. treated mice. Administration of 2 × 2.5 mg/kg/d artesunate did not prevent ECM death; 2 × 5 mg/kg/d
artesunate prevented ECM in most mice and delayed death from anemic malaria by approximately one week. Both doses of artemisone
prevented ECM in all treated mice, delayed recrudescence and prevented death. Changes in temperature and weight were in accordance with
disease severity, and the differences in overall group scores. Average values ± SD (error bars) are presented.
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0.01). Figure 6 clearly demonstrate the superior effect of
artemisone over artesunate.
The major limitation of artemisinin-type drugs is their
short half-life, which necessitates frequent administra-
tion; this leads to non-compliance, recrudescence, and
possibly the development of resistance [24,62]. As a
result, the World Health Organization recommends that
these drugs be administered together with a long half-
life anti-plasmodial drug (artemisinin combination ther-
apy; ACT). Our experiments examined whether recru-
descent parasites that appeared following artemisone
therapy displayed any drug resistance. Recrudescent
parasites (referred to as ‘recrudescent PbAus’)w e r e
Table 4 Disease pattern in PbAus-infected C57BL/6 mice
treated with artesunate or artemisone twice a day, on
days 7-9 post-inoculation
Compound Dose Infection outcome
Cerebral
malaria
Anemic
malaria
Cured
DMSO 20 μl 4/8 4/8 0/8
Artesunate 2 × 2.5 mg/kg/
d
6/8 2/8 0/8
2 × 5 mg/kg/d 1/8* 7/8* 0/8
Artemisone 2 × 2.5 mg/kg/
d
0/8* 3/8 5/8*
†
2 × 5 mg/kg/d 0/8* 0/8*
† 8/8*
†
*Significant vs. control.
†Significant vs. artesunate.
Figure 6 Overall group scores for PbAus-infected C57BL/6 mice treated with artesunate (A) or artemisone (B), twice a day on days 7-9
post-inoculation. Significant differences were seen between the control group and mice treated with 2 × 5 mg/kg/d artesunate (p < 0.05) or
artemisone (both doses; p < 0.001). The effects of 2 × 2.5 mg/kg/d artesunate or artemisone were similar, but artemisone was significantly more
effective than artesunate, at the higher dose (p < 0.001). Average values ± SD (error bars) are presented. Arrows represent injections.
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h a dp r e v i o u s l yu n d e r g o n eat h r e e - d a yt r e a t m e n tw i t h2
× 5 mg/kg/d artemisone, and were injected to naïve
mice. After an additional passage, the recrudescent
PbAus parasites were injected to C57Bl/6 mice, and
artemisone administered at 2 × 2.5 mg/kg/d; control
mice were administered DMSO. Two additional groups
of mice were infected with non-recrudescent PbAus and
similarly injected with artemisone or DMSO. The results
demonstrate a lack of parasite resistance to artemisone
(Figure 7). No significant differences in parasitaemia
were seen when comparing the two control groups.
Administration of 2 × 2.5 mg/kg/d artemisone caused
a similar, rapid drop in parasitaemia in both PbAus-
Figure 7 Average parasitemias (A) and survival (B) of C57BL/6 mice infected with recrudescent PbAus, or PbAus, and administered
artemisone twice a day, on days 7-9 post-inoculation. Recrudescent parasites were isolated from peripheral blood of C57Bl/6 mice
previously treated with 2 × 5 mg/kg/d artemisone, and were injected to naïve mice. After an additional passage, the recrudescent parasites were
injected to C57Bl/6 mice, and artemisone administered at 2 × 2.5 mg/kg/d. Two additional groups of mice were infected with non-recrudescent
PbAus and similarly treated. No significant differences were seen in either parasitemias or survival when comparing control PbAus- and
recrudescent PbAus-infected mice. Differences in parasitemias between control and treated groups were significant (p < 0.001), as were the
differences in survival rates. Average values ± SD (error bars) are presented. Arrows represent injections.
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Page 10 of 15and recrudescent PbAus-infected mice (Figure 7A). No
significant difference in survival was seen when compar-
ing the two control groups (p = 0.3), and when com-
paring treated groups (Figure 7B). An increased dose
o f2×5m g / k g / dl e dt oc o m p l e t ec u r ei n3 / 7m i c e
(Figure 7B).
A further experiment was performed in order to
examine the efficiency of artemisone-chloroquine com-
bination therapy, to prevent the cerebral symptoms
and achieve complete parasite clearance (Figure 8).
C57Bl/6 mice were infected with PbAus as previously
described, and treated on days 7-9 post-inoculation
Figure 8 Average parasitemias (A) and survival (B) of C57BL/6 mice infected with PbAus and administered artemisone or chloroquine
monotherapy, or combination therapy. The efficiency of artemisone-chloroquine combination therapy, to prevent the cerebral symptoms and
achieve complete parasite clearance, was examined. Mice were treated on days 7-9 post-inoculation (n = 7 mice per group); control mice (n =
10) were administered saline. On day 19 post-inoculation, 2 control mice had not yet succumbed to the disease, vs. 6 mice administered
chloroquine monotherapy, and 7 mice in each of the remaining treated groups. Although delayed mortality was seen in all treated groups (p <
0.05), chloroquine or artemisone monotherapy did not lead to complete cure. In contrast, all but one mouse treated by combination therapy
were completely cured.*p < 0.001, all groups. **p < 0.05, control vs. monotherapy groups.
#p < 0.05, monotherapy vs. combination therapy
groups. Arrows represent injections. Average values ± SD (error bars) are presented.
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Page 11 of 15with 2 × 5 mg/kg/d artemisone, 15 mg/kg/d chloro-
quine, or a combination of 2 × 5 mg/kg/d artemisone
and 5 or 15 mg/kg/d chloroquine. 80% of control mice
died of ECM, whereas monotherapy with either drug
caused a drop to non-detectable parasitaemia levels by
day 10 post-inoculation (Figure 8A). Administration of
artemisone was more effective than chloroquine treat-
ment: parasitaemia levels in all artemisone-treated
mice were below detection by the end of treatment,
and recrudescence was observed starting on day 15
post-inoculation. In contrast, parasitaemia levels of
mice administered chloroquine dropped to zero only
on day 10, and recrudescence was seen starting on day
13 post-inoculation. Although delayed mortality was
seen in all treated groups (p < 0.05) (Figure 8B), chlor-
oquine or artemisone monotherapy did not lead to
complete cure. The majority of mice, in both cases,
succumbed to ECM, and the rest died later at high
parasitaemia. Except for one, all mice treated by com-
bination therapy were completely cured. No significant
difference in clinical score was seen during the ECM
phase when comparing control, artemisone- and chlor-
oquine-treated groups (Figure 9A). In contrast, signifi-
cantly lower scores were seen in mice treated with
artemisone and chloroquine throughout the experi-
ment (Figure 9B).
Discussion
In this research, the efficacy of several artemisinin
derivatives was examined for treatment of ECM in ICR
and C57BL mice. The most widely used model for CM
utilizes inbred (C57BL) mice. The decision to use
genetically heterogenous ICR mice in our research, as
an additional model for CM, was made in order to
enable a more accurate reflection of human CM sus-
ceptibility and the possible effect of treatment. The
validity of ECM in outbred mice as a model for CM
has previously been demonstrated [41,63-65]. Artemi-
side and artemisone were shown to be more effective
than DHA and artesunate, two artemisinin derivatives
used in anti-malarial artemisinin-based combination
therapy. In all experiments, treatment with artemisone
led to complete cure, or reduced parasitaemia to unde-
tectable levels; recrudescence was followed by death
from either anaemic or cerebral malaria. In these
cases, the significant delay to the time of death from
anaemic malaria, or to the appearance of cerebral
symptoms, may open a considerable time window for
adequate treatment. A steady state latency, in which
non-detectable levels of parasites remain in the blood,
has been described in cases of human P. falciparum
infection [65]. As demonstrated, the recrudescent
parasites could also be completely eliminated by
repeating the artemisone treatment.
The results with artemisone demonstrate that com-
plete cure may be achieved even when treatment
is started at late stages of pathogenesis, 6 days post-
inoculation. These findings are especially important, as
human malaria is diagnosed only after clinical symptoms
are apparent, and especially so if the rapid process of
CM has been initiated. Furthermore, co-administration
of artemisone with low doses of chloroquine prevented
recrudescence and led to complete cure in all mice.
Recrudescence that appeared after monotherapy did not
cause any short-term drug resistance, as parasites iso-
lated from the recrudescent mi c ew e r ef u l l ys u s c e p t i b l e
to artemisone.
The successful use of artemisone in combination with
chloroquine, to which most strains of P. falciparum are
resistant, may be analogous to the combination of pro-
guanil and atovaquone (Malarone®). Although P. falci-
parum is resistant to both atovaquone and proguanil,
the parasite is sensitive to Malarone®, which is used for
both prophylaxis and treatment. Similarly, combination
of artemisone with a partner drug to which resistance
has developed may enable the latters reintroduction.
Although slight antagonism between artemisone and
chloroquine has been reported in in vitro tests against
P. falciparum [66], synergism or no interaction has been
observed when the drugs were tested in vivo against
Plasmodium yoelii NS or P. berghei NY, respectively.
The in vivo experiments were based on the Peter’sf o u r -
day test, in which mice are treated on the first day post-
inoculation and for an additional three days thereafter;
the analysis of results is based on blood smears taken
on day 5 post-inoculation. This approach does not
reflect the final results of the treatment (i.e. the fate of
the animals) or provide any indication of the immune
responses of the infected animals. Therefore, the Peter’s
four-day test is inadequate for estimation of the effect of
drug treatment on severe (cerebral) malaria, where
pathogenesis is most pronounced a week or more after
infection and pathology (or lack of pathology) is the
result of a prolonged innate immune response [34] and
early acquired immunity.
Artemiside appeared to be even more effective than
artemisone, but this substance has yet to be submitted to
preclinical toxicological evaluation. Nevertheless,
although it does display neurotoxicity in in vitro assays
with neuronal cell lines [34], this is substantially less than
that of DHA. It is approximately three times more active
than artemisone in vitro against P. falciparum,a n di t s
therapeutic index suggests that it will be usable in a clini-
cal setting. In principle it may act as a prodrug for
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Page 12 of 15artemisone through oxidation of the thiomorpholine ring
to the S, S-dioxide of artemisone.
Conclusions
The results show that artemiside and artemisone
are the two most effective artemisinin derivatives.
Administration of artemisone may result in complete
cure even when treatment is started at late stages of
pathogenesis; recrudescence that appeared after mono-
therapy did not cause any short-term drug resistance.
Co-administration of artemisone with low doses of chlor-
oquine prevented recrudescence and led to complete
cure in all mice. Combination of artemisone with a part-
ner drug to which resistance has developed may enable
Figure 9 Average clinical scores of C57BL/6 mice infected with PbAus and administered artemisone or chloroquine monotherapy (A),
or combination therapy (B). No significant difference in clinical score was seen during the ECM phase when comparing control, artemisone-
and chloroquine-treated groups. In contrast, significantly lower scores were seen in mice treated with artemisone and chloroquine throughout
the experiment. *p < 0.05, control vs. treated groups. Average values ± SD (error bars) are presented. Arrows represent injections.
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Page 13 of 15reintroduction of the latter. Artemiside, found even more
effective than artemisone, may represent a new option
for artemisinin-based anti-malarial therapy.
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